

1 **Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization**

2 C. Paul Morris^{1,2*}, Raghda E. Eldesouki^{1,3*}, Jaiprasath Sachithanandham^{4*}, Amary Fall¹, Julie M. Norton¹,
3 Omar Abdullah¹, Nicholas Gallagher¹, Maggie Li⁴, Andrew Pekosz^{4,5#}, Eili Y. Klein^{5,6#}, Heba H.
4 Mostafa^{1#}

5
6 ¹Johns Hopkins School of Medicine, Department of Pathology, Division of Medical Microbiology

7 ²National Institute of Allergy and Infectious Disease, National Institutes of Health

8 ³Suez Canal University, School of Medicine, Department of Histology, Genetics unit, Egypt

9 ⁴W. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins
10 Bloomberg School of Public Health

11 ⁵Department of Emergency Medicine, Johns Hopkins School of Medicine

12 ⁶Center for Disease Dynamics, Economics, and Policy, Washington DC

13 *# Contributed equally

14 Corresponding authors

15 apekosz1@jhu.edu

16 615 North Wolfe Street, rm W2116, Baltimore, MD 21205

17 eklein@jhu.edu

18 5801 Smith Ave, Davis Suite 3220, Baltimore, MD 21209

19 hmostaf2@jhmi.edu

20 Meyer B-121F, 600 N. Wolfe St, Baltimore, MD 21287

21 **Abstract**

22 **Background**

23 The variant of concern, Omicron, has become the sole circulating SARS-CoV-2 variant for the past
24 several months. Omicron subvariants BA.1, BA.2, BA.3, BA.4, and BA.5 evolved over the time, with
25 BA.1 causing the largest wave of infections globally in December 2021- January 2022. In this study, we
26 compare the clinical outcomes in patients infected with different Omicron subvariants and compare the
27 relative viral loads, and recovery of infectious virus from upper respiratory specimens.

28 **Methods**

29 SARS-CoV-2 positive remnant clinical specimens, diagnosed at the Johns Hopkins Microbiology
30 Laboratory between December 2021 and July 2022, were used for whole genome sequencing. The clinical
31 outcomes of infections with Omicron subvariants were compared to infections with BA.1. Cycle
32 threshold values (Ct) and the recovery of infectious virus on VeroTMPRSS2 cell line from clinical
33 specimens were compared.

34 **Results**

35 The BA.1 was associated with the largest increase in SARS-CoV-2 positivity rate and COVID-19 related
36 hospitalizations at the Johns Hopkins system. After a peak in January cases fell in the spring, but the
37 emergence of BA.2.12.1 followed by BA.5 in May 2022 led to an increase in case positivity and
38 admissions. BA.1 infections had a lower mean Ct when compared to other Omicron subvariants. BA.5
39 samples had a greater likelihood of having infectious virus at Ct values less than 20.

40 **Conclusions**

41 Omicron subvariants continue to associate with a relatively high positivity and admissions. The BA.5
42 infections are more while BA.2 infections are less likely to have infectious virus, suggesting potential
43 differences in infectibility during the Omicron waves.

44 **Funding**

45 Centers for Disease Control and Prevention contract 75D30121C11061, NIH/NIAID Center of Excellence
46 in Influenza Research and Surveillance contract HHS N2772201400007C, Johns Hopkins University,
47 Maryland department of health, and The Modeling Infectious Diseases in Healthcare Network (MInD)
48 under awards U01CK000589.

49 **Keyword**

50 Omicron, Cycle thresholds, Cell culture, live virus

51 **Introduction**

52 Multiple subvariants of Omicron have emerged since its first discovery in November 2021 (1, 2). In the
53 United States, BA.1 predominated in December 2021 and January 2022 then was displaced by BA.2,
54 followed by BA.2.12.1 in March and April of 2022. The BA.4 and BA.5 then displaced all other Omicron
55 sublineages, with BA.5 becoming dominant despite having an identical Spike protein sequence to BA.4
56 (<https://covid.cdc.gov/covid-data-tracker/#variant-proportions> last accessed 8/22/22). The evolution of
57 each subvariant was associated with increasing evasion of neutralizing antibodies. The BA.1 and BA.2
58 showed a large reduction in neutralization by antibodies induced by vaccination, prior infection, as well
59 as therapeutic monoclonal antibodies (3-6). The BA.2.12.1 and the BA.4/BA.5 showed increased
60 neutralization escape compared to BA.2 (7, 8).

61 The Omicron variants were first discovered in South Africa and Botswana in November 2021, however,
62 the kinetics of reporting of its subvariants were ahead in this region compared to the United States (9).
63 The South African experience revealed lower number of cases, hospital admissions, and deaths during the
64 BA.4/BA.5 wave when compared to the BA.1 wave (9, 10), even though BA.4/BA.5 caused a large
65 number of reinfections (10). As the behavior of Omicron subvariants might be impacted by the
66 differences in levels of immunity to prior infections and vaccination rates which are both significantly
67 different in the US compared to South Africa, in this study we examined the outcomes of infection with

68 Omicron subvariants for patients diagnosed at the Johns Hopkins system. In addition, we provide a
69 comparison of upper respiratory viral loads from patients infected with the Omicron subvariants and the
70 recovery of infectious virus on cell culture.

71

72 **Methods**

73 **Ethical considerations and Data availability**

74 The research was performed with a waiver of consent under the Johns Hopkins protocol IRB00221396.
75 Whole genomes that met the quality standards were made publicly available at GISAID.

76 **Specimens and Patients' Data**

77 In this retrospective observational cohort study, we used nasopharyngeal or lateral mid-turbinate nasal
78 swabs from remnant clinical specimens from the Johns Hopkins Health System (JHHS) after standard of
79 care SARS-CoV-2 diagnostic or screening testing for symptomatic and asymptomatic patients. Specimens
80 included samples obtained from across all inpatient and outpatient settings in the National Capital Region
81 (4, 11). SARS-CoV-2 testing was performed using different molecular approaches as we described before
82 (4, 6, 11-14).

83 **Sample size**

84 We included all Omicron infections identified from November 25th, 2021, the date the first Omicron
85 variant identified in our system (11), through July 17th, 2022. Because only 3 Omicron infections were
86 identified in our system in November, total infections and positivity rates were calculated from the
87 beginning of December 2021. For patients who were tested more than once, we used their initial
88 collection. Whole genome sequencing for surveillance was attempted for all positive specimens with left-
89 over volumes from JHHS and samples are collected in real-time on a daily basis. All samples with
90 genomes that did not pass a quality of coverage > 90% and mean depth >100 were excluded. Genomes

91 with unassigned lineages were excluded. For Ct and cell culture experiments, samples were randomly
92 selected from the whole cohort based on availability (Table 1).

93 **Clinical data analysis**

94 Clinical and vaccination data for patients whose samples were characterized by whole genome
95 sequencing was bulk extracted as previously detailed (4, 11) and cases with missing data were excluded.
96 Because every patient admitted to a JHHS hospital is tested for SARS-CoV-2 regardless of symptoms, we
97 used presenting complaints, ED admission diagnoses, reason for testing, and timing of testing relative to
98 admission to distinguish between patients who were admitted primarily for COVID-19 treatment from
99 incidental asymptomatic admissions. Patients with an ED diagnosis related to an upper respiratory
100 infection or with chief complaints consistent with COVID-19 (based on influenza like illness (ILI)
101 syndromic surveillance) or whose reason for testing was other than asymptomatic, were considered a
102 COVID-related admission. Patients tested under asymptomatic admission protocols were considered non-
103 COVID-related admissions. Each admission was scored based on the likelihood of the admission being
104 COVID-related based on the complaints, diagnoses, and reasons for testing. Full vaccination was based
105 on positive SARS-CoV-2 test results more than 14 days after the second shot for pfizer/BioNTech
106 BNT162b2 and Moderna mRNA-1273 or 14 days after the J&J/Janssen. In our vaccinated patients'
107 population, 65.1% received Pfizer/BioNTech, Moderna mRNA-1273 (30.1%), and the J&J/Janssen
108 COVID-19 vaccines (4.8%).

109 **Ct value analysis**

110 To ensure comparable Ct values for relative viral load analyses, Ct values of the N gene were collected.
111 For that, samples were retested with either the PerkinElmers SARS-CoV-2 kit
112 (<https://www.fda.gov/media/136410/download>, Last accessed August 17, 2022) or the CDC designed
113 primers and probes for the N gene (14).

114 **Amplicon based Sequencing**

115 Specimen preparation, extractions, and sequencing were performed as described previously (11, 15, 16).
116 Library preparation was performed using the NEBNext® ARTIC SARS-CoV-2 Companion Kit (VarSkip
117 Short SARS-CoV-2 # E7660-L). Sequencing was performed using the Nanopore GridION and analysis
118 was performed as described in (11). Sequences with coverage >90% and mean depth >100 were
119 submitted to GISAID database. Genomes with lineages assigned by Pangolin were included (coverage >
120 70%, Tables S1 details the quality of the genomes).

121 **Cell culture**

122 VeroE6TMPRSS2 (VT) cells (RRID: CVCL_YQ49) were obtained from the National Institute of
123 Infectious Diseases, Japan and are described in (5) and were processed as we described previously (11).
124 VeroE6-ACE2-TMPRSS2 (VAT) cells were obtained from the BEI resources repository and cultured in
125 an identical manner to VT cells. The cells were cultured and infected with aliquots of swab specimens as
126 previously described for VeroE6 cells (17) except that 75 µL was added to VT or VAT cells for
127 experiments that assessed parallel virus isolations. Cultures were incubated for 7 days or until cytopathic
128 effect (CPE) was obvious and SARS-CoV-2 infection was confirmed by reverse transcriptase PCR (17).
129 Wells with approximately 75% of the cells showing CPE were considered positive and the day this
130 occurred was documented.

131 **Viruses.**

132 SARS-CoV-2/USA-WA1/2020 (EPI_ISL_404895) was obtained from BEI Resources. The other SARS-
133 CoV-2 viruses used in this study were hCoV19/USA/MD-HP00076/2020 (EPI_ISL_438234),
134 hCoV19/USA/MD-HP11011/2021 (EPI_ISL_825013), hCoV19/USA/CA-VRLC088/2021
135 (EPI_ISL_2987142), hCoV19/USA/MD-HP07626/2021 (EPI_ISL_3373222), hCoV19/USA/MD-
136 HP05660/2021 (EPI_ISL_2331507), hCoV19/USA/MD-HP25001/2022 (EPI_ISL_9245416),
137 hCoV19/USA/MD-HP28972/2022 (EPI_ISL_11962964), hCoV19/USA/MD-HP32103/2022 (GISAID

138 accession number pending) and hCoV19/USA/MD-HP30386/2022 (EPI_ISL_12416220), which were all
139 isolated from COVID-19 patients at JHHS as previously described (11).

140 **Tissue culture infective dose (TCID₅₀) assay for infectious SARS-CoV-2 titer quantification**

141 The infectious virus titer was determined on VT or VAT cells using a 50% tissue culture infectious dose
142 (TCID₅₀) assay as previously described for SARS-CoV-2 (11). VT or VAT cells were grown to 90-100%
143 confluence in 96 well plates. Serial 10-fold dilutions of the virus stock were made in infection media (IM)
144 (identical to CM except the FBS was reduced to 2.5%), and then 20 µL of each dilution was added to the
145 cells in sextuplicate. The cells were incubated at 37°C with 5% CO₂ for 5 days. The cells were fixed by
146 adding 100 µL of 4% formaldehyde in PBS per well overnight and visualized by staining with 75 µL of
147 naphthol blue-black solution overnight and scored visually for cytopathic effect. A Reed and Muench
148 calculation were used to determine the TCID₅₀ per mL.

149

150 **Statistical analysis**

151 Chi-square analysis was used for categorical variables with and without correction for confounding
152 variables. For association between lineage and hospitalization or mortality, age and vaccine status were
153 controlled using Cochran-Mantel-Haenszel method utilizing 5 categories for continuous variables (3).
154 Where appropriate, Fisher Exact test was used for categorical variable comparisons. One-way ANOVA
155 and t test were used for comparing continuous independent variables. Post-hoc analysis was carried out
156 with Mann-Whitney U test with Bonferroni correction where appropriate.

157 **Results**

158 **SARS-CoV-2 positivity and Omicron subvariants trends December 2021- July 2022.**

159 The monthly SARS-CoV-2 positivity rate was highest in January 2022 (23.7%) then declined to a mean
160 of 1.6% in March 2022 before increasing again in May 2022 to a mean of 7.6% (Figure 1A). The
161 positivity rate then largely plateaued through July 2022 (Figure 1A). The predominant Omicron

162 subvariant in December 2021 and January 2022 was BA.1 (82.7% and 96.3% respectively, Figure 1B).
163 Other subvariants displaced the BA.1 including the BA.1.1 in February (58%), BA.2 in March and April
164 (52.2% and 66.9%), the BA.2.12.1 in May and June (53.6% and 49.5%), and the BA.5 in July (62.9%).
165 Notably, COVID-19 related admissions peaked in January 2022, correlating with the peak of BA.1 then
166 declined in March and April, before increasing again in May 2022 and plateauing similar to the positivity
167 rate (Figure 1C and D).

168 **Patient characteristics and outcomes in infections caused by Omicron subvariants.**

169 Of 199,378 samples tested for SARS-CoV-2 from JHHS between November 25th 2021 and July 17th
170 2022, a total of 21,007 samples were positive, of them, 11,775 were sequenced for genomic surveillance
171 and 8,377 were of high quality. After excluding repeat tests in patients and all other clades than Omicron,
172 virus genome sequencing identified a total of 6,993 unique patients who were infected with Omicron
173 subvariants. Only the major subvariants that showed high prevalence were used for further analysis (N =
174 6,954, Table 1). Subvariants BA.1.1, BA.2, BA.2.12.1, BA.4, and BA.5 were compared to subvariant
175 BA.1 (which we characterized as compared to Delta in a prior study (11)). Samples within branches from
176 subvariants were traced back to lineages used in the study (i.e. BA.1.2 would be considered BA.1, and
177 BA.1.1.2 would be considered BA.1.1, Table S1). Notably, the percentages of infections in individuals
178 who received booster vaccination increased from 22% with BA.1 to 40.8%, 37.9%, 38.6%, and 38% with
179 BA.2, BA.2.12.1, BA.4, and BA.5 (Table 1).

180 Compared to BA.1, the odds ratio for COVID-19 related hospitalization was higher with BA.1.1 (1.2, p =
181 0.45), BA.2 (1.57, p = 0.0032), BA.2.12.1 (1.62, p = 0.001), BA.4 (1.87, p = 0.023), and BA.5 (1.66, p =
182 0.021) after controlling for patients' age and vaccine status with lower likelihood of COVID-19 related
183 mortality (Table 2). Similar trends were observed when these variables were not accounted for (Table 3).
184 In general, fully vaccinated patients and those who received booster vaccination were less likely to be
185 hospitalized (0.83 (p = 0.09) and 0.92 (p = 0.47)), and different underlying conditions increased the

186 likelihood of admissions including primarily kidney disease, heart disease, and immune suppression
187 (Table 3).

188 **Omicron subvariants cycle threshold (Ct) values in upper respiratory samples.**

189 The mean Ct value of BA.1 samples (19.43) was significantly lower compared to all other subvariants
190 (BA.1.1 (22.81), BA.2 (22.74), BA.2.12.1 (22.74), BA.4 (22.56), BA.5 (21.92), one-way ANOVA, $p <$
191 0.0001, Figure 2A). This held true when comparing Ct values from symptomatic cases within the first 5
192 days of symptoms (BA.1 (18.79), BA.1.1 (22.26), BA.2 (22.06), BA.2.12.1 (21.76), BA.4 (22.39), BA.5
193 (21.41), one-way ANOVA, $p <$ 0.0001, Figure 2B), and when comparing Ct values from asymptomatic
194 patients (BA.1 (21.23), BA.1.1 (24.42), BA.2 (24.24), BA.2.12.1 (23.79), BA.4 (23.7), BA.5 (24.74),
195 one-way ANOVA, $p <$ 0.0001, Figure 2C). No differences were noted when Ct values were compared
196 between vaccinated and unvaccinated patients from all groups, however, the mean Ct of BA.1 was
197 consistently lower than the other subvariants in unvaccinated, fully vaccinated, and patients who received
198 a booster vaccination (Figure 2D). Figure 2E and Table 1 and 4 summarize the numbers tested for each
199 subvariant.

200 **Recovery of infectious virus in Omicron subvariant groups.**

201 Recovery of infectious virus was performed for 713 samples on VT cells (Table 1 and 5), the same cell
202 line that we used to compare Omicron to Delta in a prior study (11). The recovery of infectious virus was
203 higher from samples with lower mean Ct values regardless of the subvariant (Figure 3A, mean Ct for
204 positive versus negative cell culture: BA.1 (16.4 vs 20.5, $p <$ 0.0001), BA.1.1 (18.5 vs 25.1, $p =$ 0.004),
205 BA.2 (20.3 vs 24.9, $p <$ 0.0001), BA.2.12.1 (21.2 vs 23.7, $p =$ 0.19), BA.4 (19.3 vs 25.1, $p =$ 0.0001),
206 BA.5 (18.5 vs 26.4, $p <$ 0.0001). Recovery rates for Omicron subvariants were not significantly different
207 from BA.1, with the exception of BA.2 and BA.2.12.1 which consistently showed less recovery of
208 infectious virus on VT cells, regardless of patients' vaccination status, when the relative virus loads of the
209 samples were not accounted for (Figure 3B and Table 5). When we used samples with Ct values less than

210 20 to compare between groups, BA.5 showed statistically higher recovery of infectious virus (Figure 3C
211 and Table 5).

212 **Sensitivity of VAT versus VT cell lines for the recovery of infectious Omicron subvariants.**

213 To assess the difference of the recovery of infectious Omicron subvariants if we use a cell line that
214 expresses ACE-2 in addition to TMPRSS2, 332 samples were cultured side by side on both VAT and VT
215 cell lines. A significant increase in the recovery of infectious virus was notable on VAT compared to VT
216 for all samples (59.3% vs 47.3%, $P = 0.0031$, Figure 4A), as well as for samples with Ct more than 20
217 (45.3% vs 31.3%, $P = 0.012$, Figure 4B), but the difference did not reach statistical significance for
218 samples with Ct < 20 (Figure 4C and Table 6). Only BA.5 samples with Ct more than 20 showed a
219 significant difference in virus recovery between VAT and VT (Table 6).

220 To further assess if VAT cell line enhances the isolation of Omicron subvariants, we selected 4 different
221 Omicron subvariants' isolates and compared their TCID₅₀ on VAT versus VT cell lines. We included the
222 wild type strain (WAS, SARS-CoV-2/USA-WA1/2020) in addition to some pre-Omicron lineages (Table
223 7). The average log TCID₅₀ of 4 replicates per each isolate was consistently higher and mostly
224 statistically significant when VAT cells were used with an average log difference of 0.47 between VAT
225 and VT cell lines (Table 7).

226 **Reinfections caused by Omicron subvariants.**

227 To assess the possibility of reinfections with Omicron subvariants after a prior infection with Omicron,
228 we evaluated the timing of multiple positives from the same patients in our cohort. There were 170 likely
229 reinfections with lineages BA.2, BA.2.12.1, BA.4 or BA.5 based on patients having multiple positive
230 samples with an initial positive occurring prior to the first detection of that lineage. Median days from
231 initial sample to reinfection was 167 days (mean of 236). For samples with an initial infection in
232 December 2021 or January 2022, which was likely BA.1 or BA.1.1, a total of 133 were identified as
233 reinfected with another Omicron subvariant (Table 8).

234 **Discussion**

235 In this study, a large retrospective cohort of patients infected with Omicron between December 2021 (in
236 addition to three infected patients in November 2021) and July 2022 was used to compare outcomes of
237 infection by the most predominant subvariants. Our data showed that the largest peak of SARS-CoV-2
238 positivity and COVID-19 related admissions was in December 2021 and January 2022 and associated
239 with the BA.1 wave. Subsequent predominant Omicron subvariants included the BA.1.1 in February
240 2022, BA.2 in March and April 2022, BA.2.12.1 in May and June 2022, and BA.5 in July 2022. Those
241 waves correlated with a reduction in cases and admissions in February to April 2022, followed by a small
242 but plateaued increase in May to July 2022. Comparing COVID-19 related admissions for each lineage,
243 showed that there was a slight increase in the likelihood of admission in BA.1.1, BA.2, BA.2.12.1, BA.4,
244 and BA.5 compared to BA.1 but a reduction in the likelihood of mortality. Admissions were more likely
245 in patients with different comorbidities.

246 Despite the increased likelihood in admission of all subvariants studied compared to BA.1, this does not
247 necessarily mean that the other variants can inherently cause a more severe disease than BA.1. As a study
248 in South Africa did not report a difference in hospitalization rates with BA.2 compared to BA.1 (18), it
249 seems likely that other factors could contribute to increased admissions in our cohort. The differences in
250 hospitalization rates for each lineage in our study could reflect stricter criteria for admission during
251 elevated rates of infection, increased testing at home leading to only more serious cases being captured by
252 our screening methods, or seasonality, in which colder and drier months are associated with more
253 COVID-19 cases (19) as well as a potentially waning immune response leading to more severe respiratory
254 infections.

255 Infections with BA.1 were associated with the large increase in the number of cases and hospitalization in
256 December 2021 and in January 2022 (11). Even though, BA.2 displaced BA.1, its predominance did not
257 correlate with an increase in the number of cases; on the contrary, in our system, when BA.2 was
258 predominant, it was associated with a period of the least positivity rates since the emergence of Omicron

259 (March and April, 2022). Interestingly, our cell culture model showed a reduction in the recovery of
260 infectious virus from BA.2 samples which might reflect a reduction in infectivity of BA.2 in our region.
261 Remarkably, this was not a consistent pattern worldwide, and countries that included Denmark, China,
262 and Japan reported an increase in hospitalizations and death during the peak of BA.2 (20-22). This
263 indicates that the emergence, spread, and risk of different subvariants are likely dependent on many
264 factors within a community that include the immune responses due to prior infections or vaccinations.
265 Several reports showed that booster vaccination or prior COVID-19 vaccination followed by SARS-CoV-
266 2 infection are associated with an increase in the neutralizing antibodies to the Omicron subvariants (7,
267 23). This might explain the differences between countries that had a massive circulation of BA.1 followed
268 by the emergence of BA.2 and other Omicron subvariants versus other countries that experienced
269 probably the co-circulation of BA.1 and BA.2.

270 In our study, we show that BA.1 infections were associated with the highest relative virus load in upper
271 respiratory specimens when compared to the subsequent Omicron subvariants. In a previous study, when
272 we compared the relative upper respiratory viral loads in BA.1 and Delta infected patients, we didn't
273 notice a significant difference between the two variants (11). Groups from Tokyo and France did not
274 report a significant difference in viral loads between BA.1 and BA.2 infected cases (24, 25). The data
275 indicate that the selective advantage of these subvariants is likely not due to higher upper respiratory viral
276 loads. The discrepancy between our findings and prior reports might emphasize the impact of the
277 community level immune landscape that very likely differ by geographical locations.

278 It is puzzling that, in spite of the identical spike regions of the BA.4 and BA.5, the BA.5 had greater
279 success in community transmission and has become predominant, even though both variants were first
280 detected around the same time in our geographical region. Both variants also showed a marked reduction
281 in neutralization by antibodies. We also show that in our cohort, both BA.4 and BA.5 were capable of
282 causing re-infections in patients who likely had a prior infection with BA.1 or BA.1.1. In our study, we
283 show that the BA.5 is associated with more recovery of infectious virus on cell culture when we

284 controlled for the specimens' viral load. Outside of spike protein, the BA.4 and BA.5 differ in other
285 regions that include the ORF7b:L11F, N:P151S, and deletions NSP1:141–143 in BA.4 and M:D3N
286 change in BA.5 (9), in addition to a significant divergence in the 3' end. It was shown before that
287 Omicron has higher affinity to ACE-2 than Delta and that its spike uses TMPRSS2 inefficiently (26).
288 When we compared the recovery of infectious virus from different Omicron subvariants on VT versus
289 VAT, we noticed an increased sensitivity with VAT that was more notable for samples with lower
290 relative viral loads. Interestingly, an overexpression of ACE-2 was advantageous for not only Omicron
291 subvariants, but also to the original SARS-CoV-2 and pre-Omicron variants as shown by our TCID₅₀
292 comparison and consistent with prior reports (27). Further characterization of these two Omicron
293 subvariants on cell culture might reveal the genomic basis of the increased BA.5 viral fitness noted in our
294 study.

295 We previously showed that the recovery of infectious virus on cell culture inversely correlates with
296 SARS-CoV-2 specific IgG in respiratory specimens (4, 11, 28). We also showed that Omicron was
297 associated with the largest peak of reinfections in our system (29). The reduction in the recovery of
298 infectious virus from BA.2 specimens and the increased recovery of infectious virus from BA.5
299 specimens might be due to differences in the neutralization of these subvariants in upper respiratory
300 specimens by SARS-CoV-2 specific antibodies against a vaccine spike or a prior infection. We believe
301 that immune escape contributes to the increased infectivity and peaks of increased positivity and
302 reinfections.

303 This study has many limitations. First, information and samples were limited to patients tested within
304 JHHS. This means that this study lacks a true knowledge of the number of cases occurring at any time, or
305 the true number of cases in the community for a particular lineage. Additionally, information on
306 admissions elsewhere and patients vaccinated in other locations/states may not always be documented
307 within our system. Lastly, testing did not occur at the same interval from the start of symptoms which can
308 impact the viral load or ability to recover culturable virus from samples. While we used time from

309 symptoms to normalize the groups being tested for Ct values, time from the start of symptoms may not
310 fully represent the time from the start of infection and is subject to recall bias and documentation
311 challenges.

312 **Declaration of interests**

313 We declare no relevant competing interests

314 **Acknowledgements**

315 This study was only possible with the unique efforts of the Johns Hopkins Clinical Microbiology
316 Laboratory faculty and staff. HHM is supported by the HIV Prevention Trials Network (HPTN)
317 sponsored by the National Institute of Allergy and Infectious Diseases (NIAID). Funding was provided by
318 the Centers for Disease Control (contract 75D30121C11061), the Johns Hopkins Center of Excellence in
319 Influenza Research and Surveillance (HHSN272201400007C), National Institute on Drug Abuse,
320 National Institute of Mental Health, and Office of AIDS Research, of the NIH, DHHS (UM1 AI068613),
321 the NIH RADx-Tech program (3U54HL143541-02S2), National Institute of Health RADx-UP initiative
322 (Grant R01 DA045556-04S1), the Johns Hopkins University President's Fund Research Response, the
323 Johns Hopkins department of Pathology, and the Maryland department of health. EK was supported by
324 Centers for Disease Control and Prevention (CDC) MInD-Healthcare Program (Grant Number
325 U01CK000589). The views expressed in this manuscript are those of the authors and do not necessarily
326 represent the views of the National Institute of Biomedical Imaging and Bioengineering; the National
327 Heart, Lung, and Blood Institute; the National Institutes of Health, or the U.S. Department of Health and
328 Human Services.

329 **Data sharing**

330 Whole genome data were made available publicly (GISAID IDs, Table S1) and raw genomic data
331 requests could be directed to HHM.

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

332

333

334

335

336

337

338

339

340

341 References

- 342 1. Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, et al. Rapid epidemic
343 expansion of the SARS-CoV-2 Omicron variant in southern Africa. *Nature*. 2022;603(7902):679-
344 86.
- 345 2. Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, et al. Rapid epidemic
346 expansion of the SARS-CoV-2 Omicron variant in southern Africa. *Nature*. 2022;603(7902):679-
347 86.
- 348 3. Groenwold RHH, Klungel OH, van der Graaf Y, Hoes AW, Moons KGM, and
349 Pharmacoepidemiologica PW. Adjustment for continuous confounders: an example of how to
350 prevent residual confounding. *Can Med Assoc J*. 2013;185(5):401-6.
- 351 4. Luo CH, Morris CP, Sachithanandham J, Amadi A, Gaston DC, Li M, et al. Infection with the SARS-
352 CoV-2 Delta Variant is Associated with Higher Recovery of Infectious Virus Compared to the
353 Alpha Variant in both Unvaccinated and Vaccinated Individuals. *Clin Infect Dis*. 2021.
- 354 5. Matsuyama S, Nao N, Shirato K, Kawase M, Saito S, Takayama I, et al. Enhanced isolation of
355 SARS-CoV-2 by TMPRSS2-expressing cells. *Proc Natl Acad Sci U S A*. 2020;117(13):7001-3.
- 356 6. Mostafa HH, Carroll KC, Hicken R, Berry GJ, Manji R, Smith E, et al. Multi-center Evaluation of the
357 Cepheid Xpert(R) Xpress SARS-CoV-2/Flu/RSV Test. *J Clin Microbiol*. 2020.
- 358 7. Hachmann NP, Miller J, Collier AY, Ventura JD, Yu J, Rowe M, et al. Neutralization Escape by
359 SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5. *N Engl J Med*. 2022;387(1):86-8.
- 360 8. Wang Q, Guo Y, Iketani S, Nair MS, Li Z, Mohri H, et al. Antibody evasion by SARS-CoV-2 Omicron
361 subvariants BA.2.12.1, BA.4 and BA.5. *Nature*. 2022;608(7923):603-8.
- 362 9. Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, et al. Emergence of SARS-
363 CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. *Nat Med*. 2022.
- 364 10. Davies MA, Morden E, Rosseau P, Arendse J, Bam JL, Boloko L, et al. Outcomes of laboratory-
365 confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5
366 compared with previous waves in the Western Cape Province, South Africa. *medRxiv*. 2022.
- 367 11. Fall A, Eldesouki RE, Sachithanandham J, Morris CP, Norton JM, Gaston DC, et al. The
368 displacement of the SARS-CoV-2 variant Delta with Omicron: An investigation of hospital
369 admissions and upper respiratory viral loads. *EBioMedicine*. 2022;79:104008.
- 370 12. Jarrett J, Uhteg K, Forman MS, Hanlon A, Vargas C, Carroll KC, et al. Clinical performance of the
371 GenMark Dx ePlex respiratory pathogen panels for upper and lower respiratory tract infections.
372 *J Clin Virol*. 2021;135:104737.
- 373 13. Mostafa HH, Hardick J, Morehead E, Miller JA, Gaydos CA, and Manabe YC. Comparison of the
374 analytical sensitivity of seven commonly used commercial SARS-CoV-2 automated molecular
375 assays. *J Clin Virol*. 2020;130:104578.
- 376 14. Uhteg K, Jarrett J, Richards M, Howard C, Morehead E, Gearh M, et al. Comparing the analytical
377 performance of three SARS-CoV-2 molecular diagnostic assays. *J Clin Virol*. 2020;127:104384.
- 378 15. Thielen PM, Wohl S, Mehoke T, Ramakrishnan S, Kirsche M, Falade-Nwulia O, et al. Genomic
379 diversity of SARS-CoV-2 during early introduction into the Baltimore-Washington metropolitan
380 area. *JCI Insight*. 2021;6(6).
- 381 16. Morris CP, Luo CH, Amadi A, Schwartz M, Gallagher N, Ray SC, et al. An Update on SARS-CoV-2
382 Diversity in the United States National Capital Region: Evolution of Novel and Variants of
383 Concern. *Clin Infect Dis*. 2021.
- 384 17. Gniadzowski V, Morris CP, Wohl S, Mehoke T, Ramakrishnan S, Thielen P, et al. Repeat COVID-19
385 Molecular Testing: Correlation of SARS-CoV-2 Culture with Molecular Assays and Cycle
386 Thresholds. *Clin Infect Dis*. 2020.

- 387 18. Wolter N, Jassat W, von Gottberg A, and Cohen C. Clinical severity of omicron lineage BA.2
388 infection compared with BA.1 infection in South Africa. *The Lancet*. 2022;400(10346):93-6.
- 389 19. Nottmeyer LN, and Sera F. Influence of temperature, and of relative and absolute humidity on
390 COVID-19 incidence in England - A multi-city time-series study. *Environmental Research*.
391 2021;196:110977.
- 392 20. Fonager J, Bennedbaek M, Bager P, Wohlfahrt J, Ellegaard KM, Ingham AC, et al. Molecular
393 epidemiology of the SARS-CoV-2 variant Omicron BA.2 sub-lineage in Denmark, 29 November
394 2021 to 2 January 2022. *Euro Surveill*. 2022;27(10).
- 395 21. Chen LL, Abdullah SMU, Chan WM, Chan BP, Ip JD, Chu AW, et al. Contribution of low population
396 immunity to the severe Omicron BA.2 outbreak in Hong Kong. *Nat Commun*. 2022;13(1):3618.
- 397 22. Hirotsu Y, Maejima M, Shibusawa M, Natori Y, Nagakubo Y, Hosaka K, et al. SARS-CoV-2 Omicron
398 sublineage BA.2 replaces BA.1.1: Genomic surveillance in Japan from September 2021 to March
399 2022. *J Infect*. 2022;85(2):174-211.
- 400 23. Bellusci L, Grubbs G, Zahra FT, Forgacs D, Golding H, Ross TM, et al. Antibody affinity and cross-
401 variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA
402 vaccination. *Nat Commun*. 2022;13(1):4617.
- 403 24. Yuasa S, Nakajima J, Takatsuki Y, Takahashi Y, Tani-Sassa C, Iwasaki Y, et al. Viral load of SARS-
404 CoV-2 Omicron is not high despite its high infectivity. *Journal of Medical Virology*. n/a(n/a).
- 405 25. Miguères M, Dimeglio C, Mansuy JM, Abravanel F, Raymond S, Latour J, et al. Influence of
406 Nasopharyngeal Viral Load on the Spread of the Omicron BA.2 Variant. *Clinical Infectious
407 Diseases*. 2022.
- 408 26. Meng B, Abdullahi A, Ferreira I, Goonawardane N, Saito A, Kimura I, et al. Altered TMPRSS2
409 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. *Nature*. 2022;603(7902):706-
410 14.
- 411 27. Chang CW, Parsi KM, Somasundaran M, Vanderleeden E, Liu P, Cruz J, et al. A Newly Engineered
412 A549 Cell Line Expressing ACE2 and TMPRSS2 Is Highly Permissive to SARS-CoV-2, Including the
413 Delta and Omicron Variants. *Viruses*. 2022;14(7).
- 414 28. Mostafa HH, Luo CH, Morris CP, Li M, Swanson NJ, Amadi A, et al. SARS-CoV-2 infections in
415 mRNA vaccinated individuals are biased for viruses encoding spike E484K and associated with
416 reduced infectious virus loads that correlate with respiratory antiviral IgG levels. *J Clin Virol*.
417 2022;150-151:105151.
- 418 29. Morris CP, Eldesouki RE, Fall A, Gaston DC, Norton JM, Gallagher ND, et al. SARS-CoV-2
419 reinfections during the Delta and Omicron waves. *JCI Insight*. 2022.

420

421

422 Figure legends

423 **Figure 1.** SARS-CoV-2 positivity, Omicron subvariants trends, and COVID-19 related admissions,
424 December 2021- July 17, 2022. A) SARS-CoV-2 average monthly total tests, total positives, and
425 positivity rates for both symptomatic and asymptomatic testing. B) SARS-CoV-2 Omicron subvariant
426 average monthly percent to total sequenced. C) Total patients admitted each month as inpatients (includes
427 hospitalized observations) in JHHS between November 25th, 2021 and July 17, 2022 (excludes neonates
428 born in the hospital). COVID-19 hospitalizations includes any patient with a positive test in the 14 days
429 prior to admission or within the first 48 hours. D) Total patients admitted with a positive COVID-19 test
430 in the 14 days prior to admission or within the 48 hours after admission. "For COVID" is an estimate of
431 the percentage of patients that were admitted because of COVID-19 and not for a different issue then had
432 an incidental positive laboratory test with no symptoms during hospital screening. The high case only
433 includes patients flagged as having symptoms and not flagged as asymptomatic and had influenza like
434 illness (ILI) complaints and an ILI diagnosis at admission. The med case includes all high cases as well as
435 cases that only had an ILI complaint or ILI diagnosis or noted symptoms at admission and were not tested
436 asymptotically. The conservative case included cases were there was either an ILI complaint or ILI
437 diagnosis or noted symptoms at admission but were tested with an asymptomatic flag or there was no ILI
438 or symptoms noted but there was not an asymptomatic flag on the test.

439 **Figure 2.** Omicron subvariants cycle threshold (Ct) values in upper respiratory samples.
440 A) Ct values of Omicron subvariants from all samples with available Ct values (N gene). B) Ct values of
441 Omicron subvariants from samples collected 5 days or less from the onset of symptoms. For this analysis,
442 samples from asymptomatic patients were not included. C) Ct values of Omicron subvariants collected
443 from patients with "asymptomate" status in the charts. D) Ct values from Omicron subvariants groups
444 stratified by vaccination status. E) Total samples used for each Omicron subvariant. Vaccinated, fully
445 vaccinated patients who didn't receive a booster dose; boosted, patients with booster dose. Data shown as
446 violin plots and horizontal bars represent medians and quartiles.

447 **Figure 3.** Recovery of infectious virus from respiratory samples of patients infected with Omicron
448 subvariants. A) Total positives and negatives for Omicron subvariants in association with Ct values. B)
449 Percent positives for the recovery of infectious virus with Omicron subvariants for all Ct values or for
450 samples with Ct values less than 20 (C). CPE: cytopathic effect.

451 **Figure 4.** Recovery of infectious virus from respiratory samples of patients infected with Omicron
452 subvariants on VT versus VAT cell lines. A) Percent positives and negatives for Omicron subvariants. B)
453 Percent positives and negatives for samples with Ct values more than 20 (C) Percent positives and
454 negatives for Omicron subvariants with Ct values less than 20. CPE: cytopathic effect.

455

456

457

lineage	BA.1	BA.1.1	BA.2	BA.2.12.1	BA.4	BA.5
Total patients	3334	637	1041	1267	191	484
Total with complete clinical data	3285	637	1038	1234	166	337
Unvaccinated (%)	1114 (33.9)	219 (34.4)	372 (35.8)	510 (41.3)	73 (44)	124 (36.8)
Fully Vaccinated (%)	1448 (44.1)	240 (37.7)	242 (23.3)	256 (20.7)	29 (17.5)	85 (25.2)
Boosted (%)	723 (22)	178 (27.9)	424 (40.8)	468 (37.9)	64 (38.6)	128 (38)
Cell culture						
Cell culture (Total tested)	239	27	166	68	88	125
Cell culture (% positive)	63.60	48.15	27.71	41.18	56.82	60.00
Unvaccinated (% positive)	69.74	60.00	23.26	36.36	53.85	61.11
Vaccinated (% positive)	64.84	55.56	30.95	35.00	73.33	56.41
Boosted (% positive)	55.56	25.00	28.40	50.00	52.94	62.00
Ct values						
Ct values (Total tested)	1695	515	785	868	154	417
Ct values (Mean)	19.4	22.8	22.7	22.21	22.5	21.9
Ct values (SD)	4.9	5.5	5.9	5.4	5.4	5.3
Less than 5 days (total)	1013	284	416	484	75	173
Asymptomatic (total)	229	101	127	107	17	35
Unvaccinated	555	176	277	352	63	110
Vaccinated	776	195	174	182	24	80
Boosted	364	144	332	309	50	112
Disposition						
ICU (%)	1.4	2.2	1.6	1.9	1.8	1.8
ICU (Total)	45	14	17	24	3	6
Inpatient (%)	4.4	5.2	7.5	8.7	9.6	10.4
Inpatient (Total)	145	33.0	78.0	107.0	16.0	35.0
Immunosuppressed (%)	17.1	14.0	15.6	17.8	17.4	17.2
Immunosuppressed (Total)	561.0	89.0	162.0	220.0	29.0	58.0
Mean patients age	37.7	37.9	39.7	38.7	36.2	43.6

458

459 Table 1. Patients and samples used for the study.

Age/vaccine-controlled odds ratio (reference BA.1)	Hospitalization	P value compared to BA.1	Mortality	P value compared to BA.1
BA.1.1	1.2	0.45	0.76	0.64
BA.2	1.57	0.003	0.57	0.26
BA.2.12.1	1.62	0.001	0.81	0.57
BA.4	1.87	0.023	0.95	0.95
BA.5	1.66	0.021	0.22	0.081

460

461 Table 2. Odds ratios of Omicron subvariants related hospitalization compared to BA.1.

462

Variable	Odds	p
Lineage		
BA.1	0.54	<0.001
BA.1.1	0.81	0.300
BA.2	1.28	0.059
BA.2.12.1	1.59	<0.001
BA.4	1.64	0.071
BA.5	1.83	0.002
Vaccine status		
Vaccinated	0.83	0.09
Boosted	0.92	0.47
Comorbidities		
Hypertension	5.22	<0.001
Pregnancy	4.03	0.01
Lung Disease	1.97	<0.001
Kidney Disease	9.00	<0.001
Immunosuppression	7.10	<0.001
Diabetes	4.90	<0.001
Heart Failure	8.29	<0.001
Atrial Fibrillation	5.83	<0.001
Smoker	2.52	<0.001
Cerebrovascular Disease	5.07	<0.001
Cancer	2.05	<0.001
Coronary Artery Disease	7.41	<0.001

463

464 Table 3. Odds of Omicron related admissions in our study cohort.

465

		Ct value (N gene)		
		count	mean	SD
lineage	Vaccine status			
BA.1	Unvaccinated	555	19.84244	4.841083
	Vaccinated	776	19.24888	4.929083
	Boosted	365	19.19809	4.847137
BA.1.1	Unvaccinated	176	22.63063	5.857535
	Vaccinated	195	23.10762	5.296218
	Boosted	144	22.63257	5.192578
BA.2	Unvaccinated	277	22.66242	6.125257
	Vaccinated	174	22.87009	6.122025
	Boosted	332	22.7156	5.70073
BA.2.12.1	Unvaccinated	352	22.41742	5.555199
	Vaccinated	182	22.25526	5.336134
	Boosted	309	22.11507	5.525919
BA.4	Unvaccinated	63	22.05164	5.868287
	Vaccinated	24	22.41408	5.155246
	Boosted	50	23.39513	5.253949
BA.5	Unvaccinated	110	22.00935	5.182746
	Vaccinated	80	23.06307	6.267613
	Boosted	112	21.76022	4.993582

466

467 Table 4. Cycle thresholds (Ct) total, mean, and standard deviations (SD) for Omicron subvariants by
 468 vaccination status.

469

Cell culture	BA.1	BA.1.1	BA.2	BA.2.12.1	BA.4	BA.5
Total	239	27	166	68	88	125
negative	87	14	120	40	38	50
positive	152	13	46	28	50	75
P value		0.14	0.0001	0.0013	0.3	0.57
Unvaccinated						
	76	10	43	22	39	36
negative	23	4	33	14	18	14
positive	53	6	10	8	21	22
P value		0.7	0.0001	0.006	0.1	0.39
Vaccinated	91	9	42	20	15	39
negative	32	4	29	13	4	17
positive	59	5	13	7	11	22
P value		0.7	0.0003	0.022	0.77	0.43
Boosted						
	72	8	81	26	34	50
negatives	32	6	58	13	16	19
positive	40	2	23	13	18	31
P value		0.14	0.0009	0.65	0.83	0.58
Ct < 20 by vaccination status						
Unvaccinated	45	3	13	8	13	15
negatives						
	9	0	8	3	3	1
positives	36	3	5	5	10	14
P value		1	0.01	0.36	1	0.43
Vaccinated	63	3	16	4	4	13
negative	16	0	9	2	0	0
positive	47	3	7	2	4	13
P value		1	0.032	0.29	0.56	0.058
Boosted	38	3	22	3	6	17
negatives	13	2	10	0	1	1
positive	25	1	12	3	5	16
P value		0.54	0.42	0.54	0.65	0.042
Total less than 20	146	9	51	15	23	45
negatives	38	2	27	5	4	2
positives	108	7	24	10	19	43
P value		1	0.0009	0.55	0.45	0.001

470

471 Table 5. Cell culture results of Omicron subvariants (VT cell line). Two tailed P values were calculated
 472 by Fisher Exact test.

473

Cell culture	BA.1	BA.1.1	BA.2	BA.2.12.1	BA.4	BA.5	All subvariants
Total	8	27	65	66	88	78	332
VT							
negative	7	14	45	39	38	31	174
positive	1	13	20	27	50	47	158
VAT							
negative	5	11	35	32	32	20	135
positive	3	16	30	34	56	58	197
P value	0.57	0.59	0.1	0.29	0.44	0.09	0.0031
Ct < 20							
Total	2	9	25	15	23	28	102
VT							
negative	1	2	13	5	4	2	27
positive	1	7	12	10	19	26	75
VAT							
negative	1	2	9	2	2	2	18
positive	1	7	16	13	21	26	84
P value	1	1	0.39	0.39	0.67	1	0.18
Ct > 20							
Total	5	10	31	34	47	36	163
VT							
negative	5	8	24	21	29	25	112
positive	0	2	7	13	18	11	51
VAT							
negative	3	6	20	20	25	15	89
positive	2	4	11	14	22	21	74
P value	0.44	0.63	0.4	1	0.5	0.032	0.012

474

475 Table 6. Cell culture results of Omicron subvariants on VT versus VAT cell lines. Two tailed P values
 476 were calculated by Fisher Exact test.

477

Virus	Lineage	Average log TCID ₅₀		Log difference	p value
		VAT	VT		
SARS-CoV-2/USA-WA1/2020 (EPI_ISL_404895)	WAS (wild type)	7.87	7.58	0.29	0.03
hCoV19/USA/MD-HP00076/2020	A.3	8.2	7.66	0.54	0.00
hCoV19/USA/MD-HP11011/2021	B.1.1.7	7.37	6.62	0.75	0.01
hCoV19/USA/CA-VRLC088/2021	AY.1	7.95	7.87	0.08	0.60
hCoV19/USA/MD-HP07626/2021	AY.3	6.45	6.4	0.05	0.66
hCoV19/USA/MD-HP05660/2021	AY.106	7.45	6.58	0.87	0.04
hCoV19/USA/MD-HP25001/2022	BA.1.1	6.74	5.91	0.83	0.01
hCoV19/USA/MD-HP28972/2022	BA.2.12.1	6.99	6.83	0.16	0.48
hCoV19/USA/MD-HP30386/2022	BA.4	6.78	6.24	0.54	0.03
hCoV19/USA/MD-HP32103/2022	BA.5	7.58	7.03	0.55	0.01

478

479 Table 7. TCID₅₀ results of select Omicron subvariants on VT versus VAT cell lines. Two tailed P values
480 were calculated by *t* test.

481





482



		First known positive sample	
		Initial positive after December 1st 2021	Total reinfections
lineage	Vaccine status		
BA.2	Boosted	24	27
	Unvaccinated	15	18
	Vaccinated	9	13
BA.2.12.1	Boosted	20	31
	Unvaccinated	21	26
	Vaccinated	9	14
BA.4	Boosted	7	7
	Unvaccinated	6	7
	Vaccinated	3	3
BA.5	Boosted	9	10
	Unvaccinated	7	10
	Vaccinated	3	4

483

484 Table 8. Reinfections caused by Omicron subvariants with an initial infection after December 1st
485 (Omicron primary infection).


486









E


	BA.1	BA.1.1	BA.2	BA.2.12.1	BA.4	BA.5
Total	1695	515	785	868	154	417
less than 5 days	1013	284	416	484	75	173
Asymptomatic	229	101	127	107	17	35
Unvaccinated	555	176	277	352	63	110
Vaccinated	776	195	174	182	24	80
Boosted	365	144	332	309	50	112






A**VT**

■ 52.70% CPE negative
■ 47.30% CPE Positive


VAT

■ 40.70% CPE negative
■ 59.30% CPE Positive

*


B

■ 68.71% CPE negative
■ 31.29% CPE Positive




■ 54.60% CPE negative
■ 45.40% CPE Positive

*

C

■ 26.47% CPE negative
■ 73.53% CPE Positive



■ 17.65% CPE negative
■ 82.35% CPE Positive